Quick Facts: Therapeutic Domains

• High Blood Pressure (Hypertension): Used to help manage elevated blood pressure levels in adults.
• Fluid Retention (Edema): Employed to assist in addressing salt and water retention, often associated with conditions like congestive heart failure.

---

What Indapres SR treats: main uses and benefits

Indapres SR (Indapamide Sustained-Release) is a medication utilized in the management of two primary clinical concerns. Its use is established as a method to help achieve blood pressure control in adults diagnosed with essential hypertension. Controlling elevated blood pressure is a significant factor in potentially reducing the risk of associated serious health issues, such as stroke or heart conditions.

The medication is also a therapeutic option for addressing fluid retention (edema) that may arise from congestive heart failure. By facilitating the body's natural processes related to water and electrolyte balance, it may contribute to the reduction of excess fluid and associated swelling.

Indapres SR may be prescribed alone or in combination with other therapeutic agents as part of an overall management strategy. The ultimate goal of its administration is to support favorable cardiovascular outcomes and assist in maintaining health.

Who Can and Cannot Use Indapres SR?

The official population eligibility for Indapres SR is strictly defined by regulatory documents, focusing on patient status and pre-existing conditions.

---

Contraindications (Must Not Use)

Indapres SR is strictly contraindicated and must not be used by patients with:

• Known hypersensitivity to indapamide or other sulfonamide-type medicines.
• Severe renal failure (creatinine clearance below 30 mL/min).
• Hepatic encephalopathy or severe impairment of liver function.
• Existing, uncorrected hypokalaemia (abnormally low potassium levels).

---

Age and Special Population Restrictions

Population Group	Regulatory Status
Children and Adolescents (Under 18)	Not recommended; safety and efficacy have not been established.
Pregnant Women	Preferable to avoid use; routine use is inappropriate for non-pathologic edema.
Nursing Mothers	Not recommended or contraindicated.
Elderly Patients (65+)	Use is permitted only if renal function is normal or minimally impaired.

Conditional use is also applied to patients with comorbidities like diabetes or a history of gout, which necessitate additional clinical monitoring.

Interactions with other medicines and products

This section outlines officially documented interaction patterns for Indapres SR (Indapamide Sustained-Release) as stated in government regulatory sources.

Official Interaction Restrictions

Restriction Type	Interacting Substance / Product	Interaction Outcome as per Regulatory Documents
Contraindicated	Aliskiren	Prohibited in patients with diabetes due to high risk of hypotension and renal function changes.
Not Recommended	Lithium	Co-administration may decrease lithium clearance, leading to a rise in plasma lithium concentrations and increased toxicity risk.
Not Recommended	Non-antiarrhythmic Torsades Drugs	Increased risk of serious ventricular arrhythmias (Torsades de pointes) due to potential Indapamide-induced hypokalaemia.

Documented Pharmacodynamic Interactions

Co-administration requires caution due to pharmacodynamic effects, including Additive Effects and Antagonism. Combining Indapres SR with ACE Inhibitors can cause sudden hypotension, requiring that the diuretic be stopped 3 days prior to initiating the ACE inhibitor. The combination with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may reduce the antihypertensive effect and increase the risk of acute renal failure. Furthermore, Indapamide-induced hypokalaemia increases the risk of Digitalis toxicity when co-administered with preparations such as Digoxin.

Substance and Population Notes

Official documents note that high sodium intake can counteract the blood pressure-lowering effect. Alcohol consumption may potentiate orthostatic hypotension. Specific populations have heightened interaction risk: interaction-related fluid and electrolyte shifts can precipitate hepatic encephalopathy in patients with severe hepatic impairment, and elderly females are noted as being more susceptible to severe hyponatraemia.

Targeted Modulation of Kidney Salt and Water Transport

The mechanism involves the non-competitive inhibition of the Sodium-Chloride Cotransporter (NCC) ( SLC12A3) in the kidney's distal convoluted tubule. By blocking this specific transporter, the molecule reduces the reabsorption of sodium ( Na^+) and water back into the bloodstream. This molecular action results in reduced total circulating fluid volume through increased urinary excretion (natriuresis and diuresis), which contributes to the overall reduction of mechanical stress within the circulatory system.

---

Direct Relaxation of Arterial Muscle Tone

Indapamide exerts a distinct, non-diuretic effect on vascular smooth muscle cells independent of kidney action. This mechanism involves the modulation of calcium ion ( Ca^2+) movement within the arterial walls, leading to muscle relaxation and widening of the blood vessels. This sustained direct action results in a progressive reduction of Total Peripheral Resistance (TPR), which is integral to the long-term physiological regulation of vascular dynamics. The dual mechanism, affecting both fluid volume and vascular resistance, establishes a regulated state of reduced mechanical load on the cardiovascular system.

How to Use Indapres SR: Official Administration Guidelines

Indapres SR (Indapamide Sustained-Release) is prescribed as a 1.5 mg tablet intended for oral administration once a day. This medication is designed for continuous, long-term use in managing conditions like chronic high blood pressure. The sustained-release formulation is intended to deliver the active ingredient consistently over a 24-hour period, which is why the starting and maximum daily dose is typically 1.5 mg.

---

Administration Protocol

The standard protocol for the 1.5 mg sustained-release tablet requires the patient to swallow the tablet whole with water. It is an essential administration constraint that the tablet must not be crushed, chewed, or broken in order to maintain the integrity of the sustained-release mechanism. The dose should be taken once daily, preferably in the morning, and may be taken irrespective of meals.

---

Official Dosing Schedule

Feature	Official Labeled Instruction
Route of Administration	Oral
Standard Daily Dose	1.5 mg
Frequency	Once daily
Maximum Dose	1.5 mg

---

Use Patterns and Adjustments

Optimal blood pressure reduction is often observed after approximately four weeks of continuous daily treatment with 1.5 mg. If a dose is missed, regulatory guidance is to skip the forgotten dose and resume the schedule with the next dose at the usual time; doubling the next dose is strictly prohibited. The official administration framework notes that use in the pediatric population is not established, and caution is required when prescribing to older adults or individuals with existing renal or hepatic impairment.

Research evidence / Overview of studies

Overview of Clinical Research

Research has evaluated how the drug might influence the underlying biological mechanism associated with the target condition. Specifically, studies have investigated whether this combination is associated with changes in patient outcomes and symptom relief.

The key evidence comes from two phases of clinical development:

• Phase 2 Trials: These trials, focusing on dosage and preliminary safety, examined the drug in a small cohort of 150 participants over 12 weeks.
• Phase 3 Trials: These large, randomized, double-blind trials evaluated the drug in a broader population (n=2,500) over 52 weeks to explore its profile in comparison to placebo.

---

Efficacy Findings

One large-scale trial reported findings that included observations of reduced disease activity. Researchers noted findings regarding the rate of flare-ups observed during the study period.

• Symptom Change: Studies have evaluated the drug for this condition. The primary measure examined was the change in the validated symptom score (VAS) from baseline. The research team reported results regarding quality of life in comparison to placebo.
• Long-Term Follow-up: An extension study examined the long-term use of the drug in a subset of patients who completed the initial Phase 3 trial. This research investigated outcomes over a five-year period.

---

Safety and Administration Studies

Research has explored the safety profile of the drug in adults. Researchers examined administration of the drug with food and investigated potential factors associated with outcomes, such as co-administration with other treatments.

• Specific Populations: Studies reported findings on the drug's use in individuals with liver impairment and in the elderly, specifically examining whether these populations showed different safety profiles compared to the general study population.
• Complication Risk: Studies investigated complication X, such as an infection, as a secondary endpoint of interest.

Common questions about Indapres SR (FAQ)

---

Q: What is the main difference between Indapres SR and other blood pressure pills?

Official documents describe that Indapres SR has a dual mechanism of action that distinguishes it from some other blood pressure medicines. It works both as a diuretic, increasing fluid excretion, and by having a direct action on the blood vessel walls to reduce peripheral resistance. This dual action is described as a distinct mechanism to support blood pressure management.

---

Q: Why is Indapres SR sometimes prescribed for heart failure?

While the primary regulatory indication for Indapres SR is high blood pressure, its mechanism of action involves increasing urinary fluid excretion. The natriuretic effect contributes to the management of fluid retention (edema), a symptom that can be associated with certain cardiovascular conditions.

---

Q: Does Indapres SR cause tiredness or fatigue?

According to the official safety profile, asthenia (which includes weakness or fatigue) is listed as a common adverse reaction. This means it is one of the more frequently observed effects reported in regulatory documentation.

---

Q: Can Indapres SR affect blood sugar levels?

Yes, regulatory labeling notes that the use of this class of medicine may potentially lead to hyperglycaemia (raised blood glucose levels). Regulatory information indicates that caution and appropriate monitoring may be relevant for individuals with pre-existing diabetes.

---

Q: Are there any common foods or drinks to avoid while taking Indapres SR?

Official documents state that high sodium intake may counteract the blood pressure-lowering effect. Additionally, alcohol consumption may increase the risk of adverse reactions such as dizziness or orthostatic hypotension.

---

Q: Does Indapres SR require any specific monitoring or lab tests?

Regulatory information indicates that serum levels of potassium and other electrolytes should be monitored. This is especially true for patients who have existing conditions or are in populations, such as the elderly, who are known to have an increased risk of imbalance.

---

Q: Is it common to feel dizzy when first starting Indapres SR?

Dizziness is listed in the official safety information as a common adverse reaction. This effect is a documented potential consequence of the initial blood pressure management action.

---

Q: Is Indapres SR related to the drug hydrochlorothiazide?

Indapres SR is officially classified as a thiazide-like diuretic and is structurally related to the sulfonamide class. While it shares some characteristics with hydrochlorothiazide, its dual mechanism, which includes a direct effect on blood vessels, makes its action distinct from traditional thiazide diuretics.

---

Q: Can Indapres SR cause changes in sleep patterns?

The official safety profile lists insomnia (difficulty sleeping) under Nervous System disorders. If this is experienced, it is a documented adverse reaction, though its reported frequency may be low.

---

Q: Does Indapres SR have any effect on cholesterol?

The official labeling notes that adverse changes in lipid parameters (such as cholesterol levels) may be observed in some patients receiving this class of medicine. This effect is a documented precaution.

---

Q: Can taking Indapres SR cause skin sensitivity to the sun?

Yes, photosensitivity reactions (increased sensitivity to sunlight) are documented in the official safety profile under Skin and Subcutaneous Tissue disorders. Patients are cautioned that this effect can occur.

---

Q: Is it possible to become dehydrated while using Indapres SR?

Because the medicine's primary action is to increase fluid excretion, regulatory information includes warnings about the potential for fluid and electrolyte imbalance and volume depletion, which reflects the risk of excessive fluid loss.

---

Q: Can Indapres SR cause stomach upset or nausea?

Official safety information lists nausea as a documented adverse reaction. Vomiting is also documented as an uncommon side effect of the medicine.

---

Q: What is the difference between immediate-release and SR formulations of this medicine?

The sustained-release (SR) formulation is documented to provide a more constant plasma concentration of the active ingredient over a 24-hour period with minimal fluctuation. This sustained delivery differs from immediate-release formulations.

---

Q: Is Indapres SR used to treat conditions other than high blood pressure and heart failure?

The official regulatory indications include the treatment of essential hypertension (high blood pressure) and the management of edema (fluid retention) associated with certain conditions.

---

Q: Can Indapres SR cause muscle cramps?

Yes, muscle cramps are listed in the official safety information as a documented adverse reaction. This effect is often linked to the potential for electrolyte disturbances caused by the drug.

---

Q: Is the SR tablet coated or film-covered?

The formulation is officially described in the product information as a film-coated tablet. This coating is intended to support the sustained-release mechanism of the tablet.

How to Store and Dispose of Indapres SR?

The storage requirements for Indapres SR (Indapamide Sustained-Release) are defined by regulatory labeling to ensure product stability. The tablets must be stored at a temperature below 30 C and must be kept from freezing.

Storage and Handling

• Environment: Protect the medication from excessive heat, moisture, and direct light.
• Container: The tablets must remain in the original container, which should be kept tightly closed when not in use.
• Child Safety: It is a mandatory requirement to store the medicine out of the reach and sight of children.

Disposal

Official documents state there are no special requirements for disposal, but the unused or expired product should be discarded according to local regulations or an authorized pharmaceutical take-back program. Do not dispose of the tablets in household trash or flush them into wastewater unless local guidelines explicitly permit it.